Business Wire

KAYTUS

Share
KAYTUS Released MotusAI, an AI Development Platform for Highly Efficient GPU Resource Scheduling and Task Orchestration

KAYTUS, a leading IT infrastructure provider, has unveiled MotusAI, an AI development platform now accessible for trial worldwide. MotusAI is tailored for deep learning and AI development, integrating GPU and data resources alongside AI development environments to streamline computing resource allocation, task orchestration, and centralized management. It accelerates training data and manages AI model development workflows seamlessly. This platform drastically reduces resource investment, boosts development efficiency, elevates cluster computing power utilization to over 70%, and significantly enhance in large-scale training task scheduling performance.

Streamline AI Development for Cost-Effectiveness and Efficiency

The rapid expansion of enterprise AI business and AI model development brings forth challenges including low computing efficiency, complexity in model development, varied requirements for task orchestration across different scenarios, and unstable computing resources. Ensuring efficient, flexible, and stable operation of AI business is critical for enterprises to consistently derive business insights, generate revenue, and maintain competitiveness.

Optimize Resource Management for Maximum Computing Power

MotusAI efficiently allocates resources and workloads by implementing intelligent and flexible GPU scheduling. It caters to diverse AI workload demands for computing power by dynamically allocating GPU resources based on demand. With multi-dimensional and dynamic GPU resource allocation, including fine-grained GPU scheduling and support for Multi-Instance GPU (MIG), MotusAI effectively meets computing power requirements across various scenarios such as model development, debugging, and training.

Streamline Task Orchestration for Versatile Support of Various Scenario

MotusAI has revolutionized cloud-native scheduling systems. Its scheduler surpasses the community version by dramatically improving the scheduling performance of large-scale POD tasks. MotusAI achieves rapid startup and environment readiness for hundreds of PODs, boasting a five times increase in throughput and a five times decrease in latency compared to the community scheduler. This ensures efficient scheduling and utilization of computing resources for large-scale training. Moreover, MotusAI enables dynamic scaling of AI workloads for both training and inference services, supporting burst tasks and fulfilling diverse scheduling needs across various scenarios.

MotusAI empowers users to maximize computing resources, spanning from fine-grained division of single-card multiple instances to large-scale parallel computing across multiple machines and cards. By integrating features like computing power pooling, dynamic scaling, and GPU single-card reuse, MotusAI significantly enhances computing power utilization, achieving an average utilization rate of over 70%. Furthermore, it enhances computing efficiency by leveraging cluster topology awareness and optimizing network communication.

Data Transfer Acceleration for Three Times Efficiency Improvement

MotusAI excels in data transfer acceleration through innovative features such as supporting local loading and computing of remote data, which eliminates delays caused by network I/O during computation. Utilizing strategies like "zero-copy" data transfer, multi-threaded retrieval, incremental data updates, and affinity scheduling, MotusAI significantly reduces data caching cycles. These enhancements greatly improve AI development and training efficiency, resulting in 2-3 times boost in model efficiency during data training.

Reliable, and Automatically Fault-Tolerant Platform

MotusAI supports performance monitoring and alerts for computing resources, providing real-time status updates for core platform services. It employs sandbox isolation mechanisms for data with higher security levels. In case of resource failures or abnormalities, MotusAI automatically initiates fault tolerance processes to ensure the quickest possible recovery during interrupted training tasks. This approach reduces fault handling time by over 90%, on average.

Comprehensive Management of AI Model Development in One Integrated Solution

MotusAI accelerates AI development and supports every stage of large model development. From managing data samples and software stacks to designing model architectures, debugging code, training models, tuning parameters, and conducting evaluation testing, MotusAI offers a complete platform. It integrates popular development frameworks like PyTorch and TensorFlow, along with distributed training frameworks such as Megatron and DeepSpeed.

Moreover, MotusAI enables comprehensive lifecycle management of AI inferencing services, including offline and online testing, A/B testing, rolling release, service orchestration, and service decommissioning. These features collectively enhance the business value of AI technology, fostering continuous business growth.

Additionally, MotusAI provides an integrated visual management and operation interface that covers computing, networking, storage, and application resources. Operational staff can comprehensively manage, monitor, and evaluate the overall platform operation status through a single interface.

Free Trial Available

MotusAI is now available worldwide for a trial period, offering free remote access for one month, along with testing, training, and support. Users can also opt for local deployment using their own devices and environment, with local deployment testing support from KAYTUS. For more information1 and to register2, please visit Link1, Link2.

About KAYTUS

KAYTUS is a premier provider of IT infrastructure products and solutions, delivering a suite of cutting-edge, open, and environmentally friendly infrastructure solutions for cloud, AI, edge computing, and other emerging technologies. With a customer-centric approach, KAYTUS adapts flexibly to user needs through its agile business model. Learn more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513665403/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye